{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:28:29Z","timestamp":1759602509419,"version":"3.37.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40272-019-00370-6","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T06:04:15Z","timestamp":1574229855000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"22","author":[{"given":"Holly L.","family":"Pacenta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"2","key":"370_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.Cir-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125\u201335. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0127.","journal-title":"Cancer Immunol Res."},{"issue":"4","key":"370_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/mt.2014.208","volume":"23","author":"M Jonnalagadda","year":"2015","unstructured":"Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757\u201368. https:\/\/doi.org\/10.1038\/mt.2014.208.","journal-title":"Mol Ther."},{"issue":"4","key":"370_CR3","doi-asserted-by":"publisher","first-page":"e23621","DOI":"10.4161\/onci.23621","volume":"2","author":"AH Long","year":"2013","unstructured":"Long AH, Haso WM, Orentas RJ. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology. 2013;2(4):e23621. https:\/\/doi.org\/10.4161\/onci.23621.","journal-title":"Oncoimmunology."},{"issue":"10","key":"370_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.tibtech.2005.07.007","volume":"23","author":"T Hey","year":"2005","unstructured":"Hey T, Fiedler E, Rudolph R, Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 2005;23(10):514\u201322. https:\/\/doi.org\/10.1016\/j.tibtech.2005.07.007.","journal-title":"Trends Biotechnol."},{"issue":"7","key":"370_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","volume":"27","author":"H Qin","year":"2019","unstructured":"Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, et al. Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and bi-specific antitumor activity of T cells. Mol Ther. 2019;27(7):1262\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.010.","journal-title":"Mol Ther."},{"issue":"6","key":"370_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med."},{"key":"370_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22. https:\/\/doi.org\/10.1186\/s40364-017-0102-y.","journal-title":"Biomark Res."},{"issue":"9","key":"370_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.Cir-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, Fraietta JA, Patel PR, Scholler J, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T Cells. Cancer Immunol Res. 2018;6(9):1100\u20139. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0405.","journal-title":"Cancer Immunol Res."},{"issue":"17","key":"370_CR9","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940\u201350. https:\/\/doi.org\/10.1182\/blood-2011-10-387969.","journal-title":"Blood."},{"issue":"4","key":"370_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342. https:\/\/doi.org\/10.1038\/nri3405.","journal-title":"Nat Rev Immunol."},{"issue":"18 Pt 1","key":"370_CR11","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0674.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"370_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453\u201364. https:\/\/doi.org\/10.1038\/mt.2009.83.","journal-title":"Mol Ther."},{"issue":"5","key":"370_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pule","year":"2005","unstructured":"Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.016.","journal-title":"Mol Ther."},{"issue":"4","key":"370_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458\u201366. https:\/\/doi.org\/10.4161\/onci.19855.","journal-title":"Oncoimmunology."},{"issue":"1","key":"370_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T Cell survival and IS vector-dependent. Cell Rep. 2017;21(1):17\u201326. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.015.","journal-title":"Cell Rep."},{"issue":"Suppl 1","key":"370_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","volume":"132","author":"SA Grupp","year":"2018","unstructured":"Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia. J Blood. 2018;132(Suppl 1):895. https:\/\/doi.org\/10.1182\/blood-2018-99-112599.","journal-title":"J Blood."},{"issue":"8","key":"370_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341. https:\/\/doi.org\/10.1182\/blood-2016-09-738245.","journal-title":"Blood."},{"issue":"5","key":"370_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","volume":"16","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy. 2014;16(5):619\u201330. https:\/\/doi.org\/10.1016\/j.jcyt.2013.10.013.","journal-title":"Cytotherapy."},{"issue":"7","key":"370_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy. 2016;18(7):893\u2013901. https:\/\/doi.org\/10.1016\/j.jcyt.2016.04.003.","journal-title":"Cytotherapy."},{"issue":"320","key":"370_CR20","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3. https:\/\/doi.org\/10.1126\/scitranslmed.aad5222.","journal-title":"Sci Transl Med."},{"issue":"4","key":"370_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell Deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1314.","journal-title":"Cancer Discov."},{"issue":"5","key":"370_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med."},{"key":"370_CR23","unstructured":"KymriahTM (Tisagenlecleucel). [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; May 2018."},{"key":"370_CR24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/01.Hs9.0000564720.36943.22","volume":"3","author":"S Grupp","year":"2019","unstructured":"Grupp S, Maude S, Baruchel A, Laetsch TW, Driscoll T, Qayed M, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities: S1618. HemaSphere. 2019;3:746\u20137. https:\/\/doi.org\/10.1097\/01.Hs9.0000564720.36943.22.","journal-title":"HemaSphere."},{"issue":"12","key":"370_CR25","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2008;22(12):2142\u201350. https:\/\/doi.org\/10.1038\/leu.2008.251.","journal-title":"Leukemia."},{"issue":"35","key":"370_CR26","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2012.48.2315","volume":"31","author":"KR Krull","year":"2013","unstructured":"Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407\u201315. https:\/\/doi.org\/10.1200\/JCO.2012.48.2315.","journal-title":"J Clin Oncol."},{"issue":"23","key":"370_CR27","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","volume":"126","author":"SR Rheingold","year":"2015","unstructured":"Rheingold SR, Chen LN, Maude SL, Aplenc R, Barker C, Barrett DM, et al. Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/Combined relapsed\/refractory ALL. Blood. 2015;126(23):3769.","journal-title":"Blood."},{"issue":"6","key":"370_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/pbc.24918","volume":"61","author":"JK Hitzler","year":"2014","unstructured":"Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014;61(6):1126\u20138. https:\/\/doi.org\/10.1002\/pbc.24918.","journal-title":"Pediatr Blood Cancer."},{"issue":"Suppl 1","key":"370_CR29","first-page":"1280","volume":"130","author":"TW Laetsch","year":"2017","unstructured":"Laetsch TW, Maude SL, Grupp SA, Boyer MW, Harris AC, Qayed M, et al. CTL019 Therapy appears safe and effective in pediatric patients with down syndrome with relapsed\/ refractory (r\/r) acute lymphoblastic leukemia. Blood. 2017;130(Suppl 1):1280.","journal-title":"Blood."},{"issue":"2","key":"370_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-018-0164-6","volume":"9","author":"G Hucks","year":"2019","unstructured":"Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer J. 2019;9(2):10. https:\/\/doi.org\/10.1038\/s41408-018-0164-6.","journal-title":"Blood Cancer J."},{"issue":"Suppl 1","key":"370_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience. J Blood. 2018;132(Suppl 1):91. https:\/\/doi.org\/10.1182\/blood-2018-99-114152.","journal-title":"J Blood."},{"key":"370_CR32","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1016\/j.clml.2019.07.190","volume":"19","author":"M Pasquini","year":"2019","unstructured":"Pasquini M, Hu Z-H, Zhang Y, Grupp S, Hematti P, Jaglowski S, et al. Real world experience of tisagenlecleucel chimeric antigen receptor (CAR) T-cells targeting CD19 in patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) using the center for international blood and marrow transplant research (CIBMTR) cellular therapy (CT) registry. Clin Lymphoma Myeloma Leuk. 2019;19:S267. https:\/\/doi.org\/10.1016\/j.clml.2019.07.190.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"5","key":"370_CR33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/leu.2015.246","volume":"30","author":"EM Driessen","year":"2016","unstructured":"Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30(5):1184\u20137. https:\/\/doi.org\/10.1038\/leu.2015.246.","journal-title":"Leukemia."},{"issue":"374","key":"370_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):374. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med."},{"issue":"7","key":"370_CR35","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580.","journal-title":"JAMA Oncol."},{"issue":"12","key":"370_CR36","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood. 2008;111(12):5477\u201385. https:\/\/doi.org\/10.1182\/blood-2008-01-132837.","journal-title":"Blood."},{"issue":"22","key":"370_CR37","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","volume":"125","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125(22):3501\u20138. https:\/\/doi.org\/10.1182\/blood-2014-12-615757.","journal-title":"Blood."},{"issue":"13 Supplement","key":"370_CR38","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1538-7445.am2018-1631","volume":"78","author":"RK Das","year":"2018","unstructured":"Das RK, Storm J, Barrett DM. Abstract 1631: T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential. J Cancer Res. 2018;78(13 Supplement):1631. https:\/\/doi.org\/10.1158\/1538-7445.am2018-1631.","journal-title":"J Cancer Res."},{"key":"370_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.068","author":"AJ Kansagra","year":"2018","unstructured":"Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T cells in B Cell acute lymphoblastic leukemia: an expert opinion from the european society for blood and marrow transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.068.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"370_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","volume":"19","author":"J McGuirk","year":"2017","unstructured":"McGuirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy. 2017;19(9):1015\u201324. https:\/\/doi.org\/10.1016\/j.jcyt.2017.06.001.","journal-title":"Cytotherapy."},{"issue":"1","key":"370_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45\u201363. https:\/\/doi.org\/10.1038\/s41571-018-0075-2.","journal-title":"Nat Rev Clin Oncol."},{"issue":"Suppl 1","key":"370_CR42","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2018-99-115593","volume":"132","author":"S Gupta","year":"2018","unstructured":"Gupta S, Alexander S, Zupanec S, Athale U, Bassal M, Edwards E, et al. High vs low-intensity bridging chemotherapy in children with acute lymphoblastic leukemia awaiting chimeric antigen receptor T-cell therapy: a population-based study from Ontario, Canada. Blood. 2018;132(Suppl 1):1410. https:\/\/doi.org\/10.1182\/blood-2018-99-115593.","journal-title":"Blood."},{"issue":"16","key":"370_CR43","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med."},{"issue":"16","key":"370_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med."},{"issue":"13 Supplement","key":"370_CR45","doi-asserted-by":"publisher","first-page":"CT077","DOI":"10.1158\/1538-7445.am2019-ct077","volume":"79","author":"MA Pulsipher","year":"2019","unstructured":"Pulsipher MA, Han X, Quigley M, Kari G, Rives S, Laetsch TW, et al. Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel. Cancer Res. 2019;79(13 Supplement):CT077. https:\/\/doi.org\/10.1158\/1538-7445.am2019-ct077.","journal-title":"Cancer Res."},{"issue":"Supplement 1","key":"370_CR46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2018-99-115460","volume":"132","author":"MA Pulsipher","year":"2018","unstructured":"Pulsipher MA, Han X, Quigley M, Kari G, Rives S, Laetsch TW, et al. molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel. Blood. 2018;132(Supplement 1):1551. https:\/\/doi.org\/10.1182\/blood-2018-99-115460.","journal-title":"Blood."},{"key":"370_CR47","unstructured":"FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma. In: FDA News Release. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer. Accessed 4 Nov 2019."},{"issue":"10","key":"370_CR48","first-page":"664","volume":"16","author":"SL Maude","year":"2018","unstructured":"Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018;16(10):664\u20136.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"24","key":"370_CR49","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0758.","journal-title":"Clin Cancer Res."},{"issue":"25","key":"370_CR50","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208.","journal-title":"Blood."},{"issue":"9967","key":"370_CR51","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet."},{"issue":"5","key":"370_CR52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"Jeannette Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. (Hagerstown, Md: 1997). 2017;40(5):187\u201395. https:\/\/doi.org\/10.1097\/cji.0000000000000169.","journal-title":"Journal of Immunotherapy"},{"issue":"20","key":"370_CR53","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310. https:\/\/doi.org\/10.1182\/blood-2015-08-665547.","journal-title":"Blood."},{"key":"370_CR54","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320. https:\/\/doi.org\/10.1038\/ncomms12320.","journal-title":"Nat Commun."},{"issue":"12","key":"370_CR55","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.Cd-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-1020.","journal-title":"Cancer Discov."},{"issue":"6","key":"370_CR56","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4\u2009+\u2009:CD8\u2009+\u2009composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Invest."},{"issue":"Supplement 1","key":"370_CR57","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","volume":"132","author":"Elise A. Chong","year":"2018","unstructured":"Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas. J Blood. 2018;132(Suppl 1):4198. https:\/\/doi.org\/10.1182\/blood-2018-99-119502.","journal-title":"Blood"},{"issue":"Supplement 1","key":"370_CR58","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","volume":"132","author":"Amanda M. Li","year":"2018","unstructured":"Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. J Blood. 2018;132(Suppl 1):556. https:\/\/doi.org\/10.1182\/blood-2018-99-112572.","journal-title":"Blood"},{"issue":"1","key":"370_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):94\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15_suppl","key":"370_CR60","doi-asserted-by":"publisher","first-page":"10530","DOI":"10.1200\/JCO.2017.35.15_suppl.10530","volume":"35","author":"Franco Locatelli","year":"2017","unstructured":"Locatelli F, Zugmaier G, Vora A, Rossig C, Peters C, Brethon B et al. Blinatumomab use in pediatric patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (r\/r ALL) from an open-label, multicenter, expanded access study. J Clin Oncol. 2017;35(15_suppl):10530. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.10530.","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"370_CR61","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/jco.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139. https:\/\/doi.org\/10.1200\/jco.2016.67.3301.","journal-title":"J Clin Oncol."},{"key":"370_CR62","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","volume":"132","author":"R Benjamin","year":"2018","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Ciocarlie O, Jain N, et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19 + relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2018;132:896.","journal-title":"Blood."},{"key":"370_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","volume":"128","author":"SL Maude","year":"2016","unstructured":"Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2016;128:217.","journal-title":"Blood."},{"key":"370_CR64","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood-2017-10-808592","volume":"130","author":"SL Maude","year":"2017","unstructured":"Maude SL, Hucks GE, Callahan C, Baniewicz D, Fasano C, Barker C, et al. Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-Naive and CAR-Exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2017;130:1319.","journal-title":"Blood."},{"issue":"3","key":"370_CR65","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.bbmt.2017.12.018","volume":"24","author":"H Shalabi","year":"2018","unstructured":"Shalabi H, Delbrook C, Stetler-Stevenson M, Yuan C, Steinberg SM, Yates B, et al. Chimeric antigen receptor T-Cell (CAR-T) therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant (HCT). Biol Blood Marrow Transplant. 2018;24(3):S25\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.018.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"370_CR66","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884\u201392. https:\/\/doi.org\/10.1038\/s41375-018-0265-z.","journal-title":"Leukemia."},{"issue":"1","key":"370_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138. https:\/\/doi.org\/10.1038\/nm.4441.","journal-title":"Nat Med."},{"issue":"Suppl 1","key":"370_CR68","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","volume":"132","author":"LM Schultz","year":"2018","unstructured":"Schultz LM, Davis KL, Baggott C, Chaudry C, Marcy AC, Mavroukakis S, et al. Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL). Blood. 2018;132(Suppl 1):898. https:\/\/doi.org\/10.1182\/blood-2018-99-117445.","journal-title":"Blood."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00370-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00370-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00370-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T01:18:54Z","timestamp":1605748734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00370-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00370-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"20 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Theodore W. Laetsch is a\u00a0Eugene P. Frenkel Scholar in Clinical Medicine and is supported by the Norma and Jim Smith Professorship in Clinical Excellence.\u00a0No other\u00a0sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Theodore W. Laetsch is the institutional principal investigator of clinical trials funded by Novartis and has consulted for Novartis. Holly L. Pacenta and Samuel John have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}